HTG Molecular Diagnostics (Nasdaq:HTGM) a life science company whose mission is to advance precision medicine, today announced the launch of the HTG EdgeSeq Reveal. HTG EdgeSeq Reveal is a powerful software product that streamlines analysis of biomarker data from samples analyzed with the HTG EdgeSeq Precision Immuno-Oncology Panel on HTG’s EdgeSeq system.

As quoted in the press release:

“Characterization and visualization of immune response in the tumor environment continues to be an important step in developing biomarker strategies to understand the body’s immune response in relation to cancer biology and potential response to mono and combination therapies,” commented John Lubniewski, HTG’s President and COO. “Our innovative HTG EdgeSeq Reveal data analysis suite is a scalable, flexible data product that we believe will expand with new applications to support HTG’s growing translational research product portfolio,” Mr. Lubniewski added.

HTG’s new software, when coupled with the HTG EdgeSeq Precision Immuno-Oncology panel, enables applications such as the immunophenotyping of tumor infiltrating lymphocytes (TILs); monitoring of immunotherapy response biomarkers; and the elucidation of immune-escape mechanisms known to drive disease progression. Using only a single 5 µm formalin-fixed, paraffin-embedded (FFPE) tissue section, the panel profiles 1,392 genes, without the RNA extraction and complex workflow associated with standard RNA-seq methods. Together with the HTG EdgeSeq system, customers using the new HTG EdgeSeq Reveal software will have the ability to conduct molecular profiling using a wide variety of sample types, potentially enabling them to accelerate discovery, support translational applications, and determine potential biomarkers for development of companion diagnostics.

Click here to read the full press release.

Are gold stocks a good idea for 2019?

Get your free market forecast today

Give me my free report!